Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica Inc., has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business.

The acquisition, which includes products in the United States, Australia, Canada, and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthens the company's position as a vaccine supplier. Terms of the deal were not disclosed. Products being acquired in Europe are still subject to approval by European anti-trust authorities.

"Boehringer Ingelheim and Fort Dodge share a strong commitment to innovation and this will continue to be the imperative basis of all our activities as we move forward," said Hubertus von Baumbach, member of the Board of Managing Directors of Boehringer Ingelheim responsible for Finance and Animal Health. "With the closing of this deal, our attention now turns to ensuring a seamless integration of the highly committed teams of people as well as the transition of the product portfolio. We aim to jointly execute a robust business strategy that ensures the continued growth of our animal health business in the U.S. and globally by continuously providing innovation to our customers."

In the United States, equine products acquired by Boehringer Ingelheim include:

  • Rabvac 3

  • Rhinomune

  • Hyalovet

  • Vetalog

Fo